Comparative Pharmacology
Head-to-head clinical analysis: BETAPACE versus PINDOLOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETAPACE versus PINDOLOL.
BETAPACE vs PINDOLOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class III antiarrhythmic agent; prolongs cardiac action potential duration and refractory period by blocking potassium channels, primarily IKr.
Pindolol is a nonselective beta-adrenergic receptor antagonist with intrinsic sympathomimetic activity (ISA). It blocks beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and blood pressure. Its ISA partially stimulates beta receptors, leading to less bradycardia and bronchoconstriction than other nonselective beta-blockers.
Oral: 80 mg twice daily; may increase up to 160 mg twice daily as needed.
5 mg orally twice daily, titrated to 10-60 mg/day in divided doses; maximum 60 mg/day.
None Documented
None Documented
Clinical Note
moderateBopindolol + Digoxin
"Bopindolol may increase the bradycardic activities of Digoxin."
Clinical Note
moderateBopindolol + Digitoxin
"Bopindolol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderatePindolol + Digitoxin
"Pindolol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateBopindolol + Deslanoside
"Bopindolol may increase the bradycardic activities of Deslanoside."
12 hours (10-20 hours) in patients with normal renal function; prolonged in renal impairment, requiring dose adjustment
The terminal elimination half-life of pindolol is 3-4 hours. However, due to its intrinsic sympathomimetic activity, the clinical duration of beta-blockade is longer, allowing for once-daily dosing in some patients.
Renal: >90% unchanged drug (sotalol) in urine; biliary/fecal: <10%
Pindolol is excreted primarily via the kidneys (renal clearance), with 60-65% of the dose eliminated unchanged in urine. Approximately 30-40% is metabolized in the liver, and biliary/fecal excretion accounts for less than 5%.
Category C
Category A/B
Beta-Blocker
Beta-Blocker